Literature DB >> 1455880

Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer.

K Nygaard1, S Hagen, H S Hansen, R Hatlevoll, R Hultborn, A Jakobsen, M Mäntyla, H Modig, E Munck-Wikland, B Rosengren.   

Abstract

In a prospective multicenter study, 186 patients with squamous cell esophageal carcinoma, who after evaluation were considered suitable for surgery, were randomized to 4 treatment groups: Group 1, surgery alone; Group 2, pre-operative chemotherapy (cisplatin and bleomycin) and surgery; Group 3, pre-operative irradiation (35 Gy) and surgery; Group 4, pre-operative chemotherapy, radiotherapy, and surgery. Three-year survival was significantly higher in the pooled groups receiving radiotherapy as compared with the pooled groups not receiving radiotherapy. Comparison of the groups having pre-operative chemotherapy with those not having chemotherapy showed no significant difference in survival. Female patients had a significantly better survival than males. The results indicate that pre-operative irradiation had a beneficial effect on intermediate term survival, whereas the chemotherapy regime used did not influence survival.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455880     DOI: 10.1007/bf02067069

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  15 in total

Review 1.  The linear-quadratic formula and progress in fractionated radiotherapy.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  1989-08       Impact factor: 3.039

2.  Clinical trial methodology.

Authors:  R Peto
Journal:  Biomedicine       Date:  1978-09

3.  The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C.

Authors:  M Gignoux; A Roussel; B Paillot; M Gillet; P Schlag; J P Favre; O Dalesio; M Buyse; N Duez
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

4.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Authors:  R Peto; M C Pike
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

5.  Preoperative radiotherapy for carcinoma of the esophagus.

Authors:  B Launois; D Delarue; J P Campion; M Kerbaol
Journal:  Surg Gynecol Obstet       Date:  1981-11

6.  Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus.

Authors:  A D Hilgenberg; R W Carey; E W Wilkins; N C Choi; D J Mathisen; H C Grillo
Journal:  Ann Thorac Surg       Date:  1988-04       Impact factor: 4.330

7.  Irradiation, chemotherapy and surgery in esophageal cancer: a randomized clinical study. The first Scandinavian trial in esophageal cancer.

Authors:  A P Andersen; P Berdal; F Edsmyr; S Hagen; R Hatlevoll; K Nygaard; P Ottosen; P Peterffy; H Kongsholm; K Elgen
Journal:  Radiother Oncol       Date:  1984-10       Impact factor: 6.280

8.  Improved survival in squamous esophageal cancer. Preoperative chemotherapy and irradiation.

Authors:  M B Popp; D Hawley; J Reising; G Bongiovanni; R Weesner; C J Moomaw; O Martelo; B Aron
Journal:  Arch Surg       Date:  1986-11

9.  The hazard of accelerated tumor clonogen repopulation during radiotherapy.

Authors:  H R Withers; J M Taylor; B Maciejewski
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

10.  Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report.

Authors:  C J Coonley; M Bains; B Hilaris; R Chapman; D P Kelsen
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

View more
  121 in total

1.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

2.  [No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma].

Authors:  R Fietkau
Journal:  Strahlenther Onkol       Date:  1999-05       Impact factor: 3.621

Review 3.  Multimodality therapy for gastroesophageal cancers.

Authors:  Kenneth K Wang
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

4.  Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis.

Authors:  Dong-Bin Wang; Xun Zhang; Hong-Li Han; Yi-Jun Xu; Da-Qiang Sun; Zhen-Liang Shi
Journal:  Dig Dis Sci       Date:  2012-06-14       Impact factor: 3.199

Review 5.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

6.  Clinical outcome and long-term survival rates after esophagectomy are not determined by age over 70 years.

Authors:  J Johansson; B Walther
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

7.  [Neoadjuvant therapy for squamous cell carcinoma of the esophagus].

Authors:  F Lordick
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

Review 8.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

Review 9.  Surgical management of esophageal malignancy.

Authors:  Dennis Blom
Journal:  Curr Gastroenterol Rep       Date:  2003-06

10.  Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis.

Authors:  Hai-Lin Jin; Hong Zhu; Ting-Sheng Ling; Hong-Jie Zhang; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.